<DOC>
	<DOCNO>NCT02960945</DOCNO>
	<brief_summary>This study ass metabolite pharmacokinetic ( PK ) profile single dose CTP-543 compare single dose Jakafi® healthy volunteer .</brief_summary>
	<brief_title>Open-Label Crossover Study Comparing CTP-543 Jakafi®</brief_title>
	<detailed_description>The crossover design ass safety , tolerability , PK metabolite profile single dose CTP-543 compare single dose Jakafi . Approximately 12 healthy volunteer enrol open label study .</detailed_description>
	<criteria>Healthy adult male females 18 50 year age , inclusive Body weight ≥ 50 kg BMI within range 18 30 kg/m2 , inclusive History clinically significant central nervous system ( eg , seizure ) , cardiac , pulmonary , metabolic , renal , hepatic , gastrointestinal ( GI ) condition PR interval &gt; 220 msec QRS duration &gt; 120 msec QTcF interval &gt; 450 msec obtain screen visit prior first dose study drug History herpes zoster Hemoglobin , white blood cell , platelet level low reference limit screen prior first dose study drug Liver function test great upper limit normal Positive blood screen human immunodeficiency virus ( HIV antibody ) , hepatitis B virus surface antigen , hepatitis C virus antibody Urinalysis positive protein glucose A positive screen alcohol , drug abuse , tobacco use Donation blood , plasma blood product prior screen A positive tuberculosis test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>